A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
Abstract
Yutrepia (Liquidia), a dry powder inhaler formulation of the prostacyclin analog treprostinil, has been approved by the FDA to improve exercise ability in adults with pulmonary arterial hypertension (PAH; WHO Group 1) or pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso DPI, another treprostinil dry powder inhaler, was approved earlier for the same indication.
Fields of Study & Subjects
Pulmonary Hypertension Research and Treatments
Inhalation and Respiratory Drug Delivery
Vascular Anomalies and Treatments
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1748
- Pages
- 27–28
- Publication date
- 6 February 2026
- Language
- EN